Low-Dose Versus Standard-Dose Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multicenter Randomized Phase III Trial The Systemic Therapy in Advancing or Metastatic ...

Transdermal estradiol patches show similar PSA response to LHRHa when combined with ARPIs in metastatic prostate cancer. The STAMPEDE trial indicates tE2 patches offer a favorable safety profile, ...

Dr. Nicholas James discusses why it is important to identify which patients with high-risk prostate cancer will truly benefit from intensified treatment. It is important to target intensified therapy ...

Radiation therapy is often thought of as a treatment that only has a role in early-stage disease. This is no longer the case, and this approach to treatment can be used in several different ways even ...

Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy ...

Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent, according to the results of one of the largest ever clinical trials for prostate ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

An artificial intelligence (AI) project has demonstrated progress towards developing personalised prostate cancer treatments, researchers reported. A team from University College London (UCL) used an ...